Comparison of systemic inflammation biomarkers in infected and uninfected populations. by Lu Han (151620)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Glucose/galactose selectively alters ISG protein not RNA levels in interferon-primed cells. by Tyron Chang (9922533)

This figure shows the forest plot for the multivariable logistic regression found in Table 1. by Scott J. Halperin (17835402)

Simulation-based assessment of driving confidence in hazardous situations under different warning levels by Erlong Lou (22420652)

“…Specifically, in the Tun, compared to the no-warning condition, the average driving speed decreased by 16.38%, and speed variability StdV decreased by 27.75%. …”

PCAIs suppress and disrupt the levels of vinculin punctates in NCI-H23 cells. by Matthew D. Gregory (19929096)

Distribution of samples according to the geographic origin of the infection, <i>Leishmania</i> species, and LRV1 statutes. by Fredy A. Pazmiño (20613765)

Analyze data. by Xinhui Zhang (1624039)

Subjects:

Mouse spinal cord injury strike parame. by Xinhui Zhang (1624039)

Subjects:

NeuN expression and neuronal apoptosis in Sham and severely injured groups. by Xinhui Zhang (1624039)

Subjects:

Constructing the T10 spinal cord injury model. by Xinhui Zhang (1624039)

Subjects:

Expression of NeuN and CIRBP proteins in Sham and severely injured groups. by Xinhui Zhang (1624039)

Subjects:

Expression of IBA1 and CIRBP proteins in Sham and severely injured groups. by Xinhui Zhang (1624039)

Subjects:

Statistically Significant Results for Heart Rate Variability (HRV) Indices with Judgment Variables as Covariates. by David Vagni (8060432)

Subjects:

Significant clusters: Coronal PET images showing brain regions with significant (p < 0.001 and K > 50) metabolic inhibition (A-G) and activation (H-I) in rats following cocaine sel... by Christopher Rowan (21499924)

Age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Age-standardized prevalence rates of gynecological diseases across 21 GBD regions, by SDI, from 1990 to 2021. by Xiaofeng He (2618752)

Subjects:

Estimated annual percentage change in age-standardized prevalence rates of gynecological diseases across 204 countries and territories in 2021. by Xiaofeng He (2618752)

Subjects:

Prevalence and trends of gynecological diseases (GDs) among women of childbearing age, by age group and SDI. by Xiaofeng He (2618752)

Subjects: